All and adverse DNA sequence variants/mutations among 182 patients with PMF
| . | Patients . | P . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| All (n = 182) . | JAK2 mutated (n = 109; 60%) . | CALR mutated (n = 40; 22%) . | MPL mutated (n = 11; 6%) . | Triple negative (n = 22; 12%) . | |||||||
| No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | ||
| No. of patients with DNA sequence variants/mutations other than JAK2/CALR/MPL | .24 | ||||||||||
| 0 | 35 | 19 | 19 | 17 | 11 | 27.5 | 1 | 9 | 4 | 18 | |
| 1 | 64 | 35 | 36 | 33 | 15 | 37.5 | 7 | 64 | 6 | 27 | |
| 2 | 48 | 27 | 30 | 28 | 11 | 27.5 | 2 | 18 | 5 | 23 | |
| 3 or more | 35 | 19 | 24 | 22 | 3 | 7.5 | 1 | 9 | 7 | 32 | |
| No. of patients with adverse DNA sequence variants/mutations other than JAK2/CALR/MPL | .3 | ||||||||||
| 0 | 80 | 44 | 43 | 39 | 23 | 57.5 | 5 | 45.5 | 9 | 41 | |
| 1 | 70 | 38 | 45 | 41 | 14 | 35 | 5 | 45.5 | 6 | 27 | |
| 2 | 23 | 13 | 16 | 15 | 2 | 5 | 0 | 5 | 23 | ||
| 3 or more | 9 | 5 | 5 | 5 | 1 | 2.5 | 1 | 9 | 2 | 9 | |
| Variants/mutations | |||||||||||
| ASXL1 | 65 | 36 | 38 | 35 | 14 | 35 | 3 | 27 | 10 | 45 | .73 |
| TET2 | 33 | 18 | 21 | 19 | 7 | 18 | 2 | 18 | 3 | 14 | .94 |
| SRSF2 | 32 | 18 | 21 | 19 | 2 | 5 | 4 | 36 | 5 | 23 | .05 |
| U2AF1 | 30 | 16 | 25 | 23 | 2 | 5 | 1 | 9 | 2 | 9 | .04 |
| CBL | 9 | 5 | 7 | 6 | 1 | 3 | 0 | 1 | 5 | .66 | |
| KIT | 2 | 1 | 1 | 1 | 0 | 0 | 1 | 5 | .39 | ||
| RUNX1 | 8 | 4 | 7 | 6 | 1 | 3 | 0 | 0 | .4 | ||
| CEBPA | 16 | 9 | 9 | 8 | 3 | 8 | 1 | 9 | 3 | 14 | .86 |
| SH2B3 | 11 | 6 | 9 | 8 | 0 | 0 | 2 | 9 | .21 | ||
| . | Patients . | P . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| All (n = 182) . | JAK2 mutated (n = 109; 60%) . | CALR mutated (n = 40; 22%) . | MPL mutated (n = 11; 6%) . | Triple negative (n = 22; 12%) . | |||||||
| No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | ||
| No. of patients with DNA sequence variants/mutations other than JAK2/CALR/MPL | .24 | ||||||||||
| 0 | 35 | 19 | 19 | 17 | 11 | 27.5 | 1 | 9 | 4 | 18 | |
| 1 | 64 | 35 | 36 | 33 | 15 | 37.5 | 7 | 64 | 6 | 27 | |
| 2 | 48 | 27 | 30 | 28 | 11 | 27.5 | 2 | 18 | 5 | 23 | |
| 3 or more | 35 | 19 | 24 | 22 | 3 | 7.5 | 1 | 9 | 7 | 32 | |
| No. of patients with adverse DNA sequence variants/mutations other than JAK2/CALR/MPL | .3 | ||||||||||
| 0 | 80 | 44 | 43 | 39 | 23 | 57.5 | 5 | 45.5 | 9 | 41 | |
| 1 | 70 | 38 | 45 | 41 | 14 | 35 | 5 | 45.5 | 6 | 27 | |
| 2 | 23 | 13 | 16 | 15 | 2 | 5 | 0 | 5 | 23 | ||
| 3 or more | 9 | 5 | 5 | 5 | 1 | 2.5 | 1 | 9 | 2 | 9 | |
| Variants/mutations | |||||||||||
| ASXL1 | 65 | 36 | 38 | 35 | 14 | 35 | 3 | 27 | 10 | 45 | .73 |
| TET2 | 33 | 18 | 21 | 19 | 7 | 18 | 2 | 18 | 3 | 14 | .94 |
| SRSF2 | 32 | 18 | 21 | 19 | 2 | 5 | 4 | 36 | 5 | 23 | .05 |
| U2AF1 | 30 | 16 | 25 | 23 | 2 | 5 | 1 | 9 | 2 | 9 | .04 |
| CBL | 9 | 5 | 7 | 6 | 1 | 3 | 0 | 1 | 5 | .66 | |
| KIT | 2 | 1 | 1 | 1 | 0 | 0 | 1 | 5 | .39 | ||
| RUNX1 | 8 | 4 | 7 | 6 | 1 | 3 | 0 | 0 | .4 | ||
| CEBPA | 16 | 9 | 9 | 8 | 3 | 8 | 1 | 9 | 3 | 14 | .86 |
| SH2B3 | 11 | 6 | 9 | 8 | 0 | 0 | 2 | 9 | .21 | ||